Innovative Pharmaceutical Biotech (HK:0399) has released an update.
Innovative Pharmaceutical Biotech Limited announced the extension of their collaboration with Tsinghua University, Beijing, to exclusively commercialize an oral insulin product, with an expected market launch in Q1 2026. The product, anticipated to be the first of its kind in the market, is projected to meet the growing demand for innovative insulin solutions in China, promising a stable revenue source post-launch. The company’s phase III clinical trials were somewhat delayed due to the pandemic but continue to progress with 400 patients enrolled.
For further insights into HK:0399 stock, check out TipRanks’ Stock Analysis page.
